Metabolic disorders in general and hypercholesterolemia in particular is a primary health concern affecting the lives of over 1.8 billion across the globe. Left unnoticed or unattended, this leads to cardiovascular disorders (CVD) which affects over 532 million people globally. Accounted for more than 19 million deaths, CVD is responsible for 32% deaths worldwide.

These alarming numbers are only seeing a steep rise in numbers due to lifestyle patterns and eating habits. It is worth highlighting that a meagre 10% reduction in blood LDL cholesterol levels in hypercholesterolemic patients can reduce the risk of heart diseases by 50%. Statins have known to be the immediate resort taken by most hypercholesterolemic patients for over a decade now. While they have proven their efficacy to reduce cholesterol levels and in turn prevent plaque formation in the arteries, they have severe side effects thus causing several individuals to discontinue their usage. NBI has invested the last few years working on a potent formulation of active molecules of natural origin with proven efficacy and no reported side effects.

Read more about CHOLESTEROL>> Commercial >> Science